CKDB-501A

DRUG3 trials

Sponsors

CKD Bio Corporation

Conditions

Glabellar LinesPost-stroke Upper Limb Spasticity

Phase 1

Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines

CompletedNCT05292638

CKD Bio CorporationGlabellar Lines

Start: 2022-02-15End: 2022-06-10Updated: 2022-11-17

Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity

CompletedNCT05382767

CKD Bio CorporationPost-stroke Upper Limb Spasticity

Start: 2022-06-02End: 2022-12-08Updated: 2023-03-28

Phase 3

Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial

CompletedNCT05804656

CKD Bio CorporationGlabellar Lines

Start: 2023-04-13End: 2023-11-20Updated: 2023-12-12

Related Papers

Efficacy and Safety of <scp>CKDB</scp>‐<scp>501A</scp> in Treating Moderate‐To‐Severe Glabellar Lines: A Randomized, Double‐Blind, Active‐Controlled, Multi‐Center Phase <scp>III</scp> Trial

Journal of Cosmetic Dermatology2025-06-30